



Marksans Pharma Ltd.

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, C-1, Block -G
Bandra - Kurla Complex,
Bandra (E), Mumbai - 400051.

07th February, 2015

Sub: Unaudited Financial Results for the Quarter ended 31st
December, 2014 and Limited Review Report thereon

Dear Sir,

In terms of Clause 41 of the Listing Agreement, enclosed herewith kindly find Unaudited Financial Results of the Company for the Quarter ended 31st December, 2014 (both Standalone and Consolidated) approved by the Board of Directors at its meeting held today, i.e., 07th February, 2015 along with Limited Review Report thereon.

You are requested to note the above in your records.

Thanking You.

Yours faithfully,
For Marksans Pharma Limited

Harshavardhan Panigrahi
Company Secretary & Manager-Legal

Enclosed: as above

CIN : L24110MH1992PLC066364

www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com



N. K. MITTAL & ASSOCIATES

Tel.: 7208011789
Mob.: 9892640589

CHARTERED ACCOUNTANTS

Office No. 620, 6th Floor, Pearl Plaza, Opp Andheri Railway Station, Near Mc Donald's, Andheri (West), Mumbai - 400 058.
E-mail : nkmittalandassociates@gmail.com / nkm@nkmittal.com / ca_mittal@rediffmail.com • Website : www.nkmittal.com

N. K. Mittal

B.Com, FCA, LLB, EMBA

LIMITED REVIEW REPORT FOR THE PERIOD ENDED 31.12.2014

We have reviewed the accompanying statement of unaudited financial results of MARKSANS PHARMA LTD for the period ended 31st December, 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards¹ and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N. K. MITTAL & ASSOCIATES
Chartered Accountants


N.K. MITTAL
(Proprietor)
M.No.46785
Place: Mumbai
Date: 07.02.2015



(₹ in Million)

[Handwritten signature]

B INVESTOR COMPLAINTS		Quarter ended 31.12.2014
Pending at the beginning of the quarter		1
Received during the quarter		9
Disposed of during the quarter		9
Remaining unresolved at the end of the quarter		1

Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 07.02.2015.
- 2 The Consolidated Financial Statements include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (U.K.) Limited.
- 3 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 4 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.



For MARKSANS PHARMA LIMITED

Place: Mumbai.
Date: 07.02.2015
www.marksanspharma.com

MARK SALDANHA
Managing Director.